Literature DB >> 25366041

Diabetes: statins for microvascular complications-all but the kidney.

Kumar Sharma1, Loki Natarajan2.   

Abstract

A new study shows that statin therapy before diagnosis of diabetes mellitus is not associated with an increased risk of microvascular disease and might even be beneficial for retinopathy and neuropathy. These data suggest a potential protective effect of statins in specific complications, which should be further investigated in randomized controlled trials.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25366041      PMCID： PMC4337890          DOI： 10.1038/nrneph.2014.203

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  6 in total

1.  The Danish National Hospital Register. A valuable source of data for modern health sciences.

Authors:  T F Andersen; M Madsen; J Jørgensen; L Mellemkjoer; J H Olsen
Journal:  Dan Med Bull       Date:  1999-06

2.  Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study.

Authors:  Sune F Nielsen; Børge G Nordestgaard
Journal:  Lancet Diabetes Endocrinol       Date:  2014-09-09       Impact factor: 32.069

Review 3.  HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Authors:  Suetonia C Palmer; Sankar D Navaneethan; Jonathan C Craig; David W Johnson; Vlado Perkovic; Jorgen Hegbrant; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-05-31

4.  Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Valentine Charlton-Menys; David A DeMicco; John H Fuller
Journal:  Am J Kidney Dis       Date:  2009-06-21       Impact factor: 8.860

5.  Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study.

Authors:  Mahboob Rahman; Wei Yang; Sanjeev Akkina; Arnold Alper; Amanda Hyre Anderson; Lawrence J Appel; Jiang He; Dominic S Raj; Jeffrey Schelling; Louise Strauss; Valerie Teal; Daniel J Rader
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-15       Impact factor: 8.237

6.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Authors:  Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.